Clinical Summary: The Efficacy of Cognitive-Behavioral Therapy in Bipolar Disorder: A Quantitative Meta-Analysis
Patients with bipolar disorder often continue to have residual symptoms, poor treatment adherence, and repeated relapses despite pharmacotherapy, with only 30% returning to their previous level of social and professional functioning 1 year after an episode. This meta-analysis asks the practical question clinicians face every day: what added value does cognitive-behavioral therapy provide when it is used alongside medication?
Key Findings
- Across 12 randomized clinical trials, adjunctive cognitive-behavioral therapy had a significant posttreatment overall effect size of d = -0.42 (95% CI, -0.51 to -0.34; P < .05); after correcting for sample size, the effect remained significant at D = -0.20 (95% CI, -0.29 to −0.11; P < .05).
- At posttreatment, the strongest domain-specific benefit was for treatment adherence at d = -0.53, P < .05, compared with d = -0.44, P < .05 for clinical symptoms, d = -0.49, P < .05 for cognitive-behavioral etiopathogenetic mechanisms, and d = -0.36, P < .05 for quality of life.
- Adjunctive cognitive-behavioral therapy did not show a significant posttreatment effect on relapse and/or recurrence, with d = -0.28.
- From posttreatment to 6 months, the overall effect remained significant but smaller at d = -0.27 (95% CI, -0.39 to -0.16), and after sample-size correction remained significant at D = -0.25, VAR D = 0.009, P < .05.
- Beyond 12 months, the apparent benefit was less stable: the uncorrected overall effect was d = -0.27 (95% CI, -0.40 to -0.13), but after correcting for sample size it was no longer significant at D = -0.06, VAR D = 0.03, P > .05.
Use cognitive-behavioral therapy as an adjunct to medication in bipolar disorder when the goal is to improve symptoms, treatment adherence, and cognitive-behavioral targets in the short term. Do not rely on adjunctive cognitive-behavioral therapy alone to reduce relapse and/or recurrence, and expect follow-up benefits to attenuate over time.
Practice Implications
- Consider adjunctive cognitive-behavioral therapy for patients with bipolar disorder who have residual symptoms or difficulty adhering to medication, because posttreatment adherence improved with a medium effect size of d = -0.53, P < .05.
- Set expectations with patients that short-term gains are most consistent for symptoms, adherence, and cognitive-behavioral mechanisms, while relapse and/or recurrence did not improve significantly at posttreatment (d = -0.28).
- Monitor patients beyond the end of therapy rather than assuming benefits will persist, because the overall effect at > 12 months was no longer significant after sample-size correction (D = -0.06, VAR D = 0.03, P > .05).
- Functional recovery may need added support beyond cognitive-behavioral therapy, since quality of life showed a significant posttreatment effect (d = -0.36, P < .05) but was not significant during follow-up.
